Jürgen Haas1, Alexander Schwarz1, Mirjam Korporal-Kunke1, Sven Jarius1, Heinz Wiendl2, Bernd C Kieseier3, Brigitte Wildemann4. 1. Department of Neurology, University Hospital of Heidelberg, Germany. 2. Department of Neurology - Inflammatory Disorders of the Nervous System and Neurooncology, University of Münster, Germany. 3. Department of Neurology, University of Düsseldorf, Germany. 4. Department of Neurology, University Hospital of Heidelberg, Germany brigitte.wildemann@med.uni-heidelberg.de.
Abstract
BACKGROUND: In multiple sclerosis (MS), disturbed T-cell homeostasis affects both conventional CD4(+) T cells (Tcon) and regulatory T cells (Treg). Functionally, this is linked to a loss of Treg-suppressive properties. Concerns exist as to whether fingolimod might further aggravate Treg dysfunction by inhibiting thymic egress and, thus, promoting premature immunosenescence. OBJECTIVE: The objective of this paper is to investigate whether fingolimod, by sequestration of developing cells in the thymus, might deteriorate numeric and/or functional disequilibrium of T-cell subtypes. METHODS: We assessed numbers and phenotypes of blood Tcon and Treg in 74 MS patients treated with fingolimod and in 37 healthy donors. Treg and Tcon were also analyzed for immunoreactivity, suppressive function, sphingosine-1-phosphate-triggered (S1P) trafficking, and S1P-receptor expression. This was complemented by assessing surrogate markers of thymic T-cell development, including frequencies of cells expressing T-cell receptors (TCR) of dual specificity, and TCR diversity in Treg. RESULTS: Fingolimod did not negatively affect naive T-cell phenotypes or markers of thymic T-cell development. By reducing CCR7-expressing Tcon, fingolimod increased relative proportions of Treg. As a result of this shift, fewer proliferative CCR7(-) Tcon became enriched and Treg-dysfunction was indirectly reversed. CONCLUSION: These observations argue against harmful interference of fingolimod with thymic T-cell output that, particularly in pediatric MS, might possibly counteract its beneficial effects.
BACKGROUND: In multiple sclerosis (MS), disturbed T-cell homeostasis affects both conventional CD4(+) T cells (Tcon) and regulatory T cells (Treg). Functionally, this is linked to a loss of Treg-suppressive properties. Concerns exist as to whether fingolimod might further aggravate Treg dysfunction by inhibiting thymic egress and, thus, promoting premature immunosenescence. OBJECTIVE: The objective of this paper is to investigate whether fingolimod, by sequestration of developing cells in the thymus, might deteriorate numeric and/or functional disequilibrium of T-cell subtypes. METHODS: We assessed numbers and phenotypes of blood Tcon and Treg in 74 MS patients treated with fingolimod and in 37 healthy donors. Treg and Tcon were also analyzed for immunoreactivity, suppressive function, sphingosine-1-phosphate-triggered (S1P) trafficking, and S1P-receptor expression. This was complemented by assessing surrogate markers of thymic T-cell development, including frequencies of cells expressing T-cell receptors (TCR) of dual specificity, and TCR diversity in Treg. RESULTS:Fingolimod did not negatively affect naive T-cell phenotypes or markers of thymic T-cell development. By reducing CCR7-expressing Tcon, fingolimod increased relative proportions of Treg. As a result of this shift, fewer proliferative CCR7(-) Tcon became enriched and Treg-dysfunction was indirectly reversed. CONCLUSION: These observations argue against harmful interference of fingolimod with thymic T-cell output that, particularly in pediatric MS, might possibly counteract its beneficial effects.
Authors: Aina Teniente-Serra; José Vicente Hervás; Bibiana Quirant-Sánchez; María José Mansilla; Laia Grau-López; Cristina Ramo-Tello; Eva María Martínez-Cáceres Journal: CNS Neurosci Ther Date: 2016-04-15 Impact factor: 5.243
Authors: Georgios K Vasileiadis; Efthymios Dardiotis; Athanasios Mavropoulos; Zisis Tsouris; Vana Tsimourtou; Dimitrios P Bogdanos; Lazaros I Sakkas; Georgios M Hadjigeorgiou Journal: Auto Immun Highlights Date: 2018-11-10
Authors: Jürgen Haas; Cornelia Würthwein; Mirjam Korporal-Kuhnke; Andrea Viehoever; Sven Jarius; Tobias Ruck; Steffen Pfeuffer; Sven G Meuth; Brigitte Wildemann Journal: Front Immunol Date: 2019-06-04 Impact factor: 7.561
Authors: Kyle Malone; Andrea C Diaz Diaz; Jennifer A Shearer; Anne C Moore; Christian Waeber Journal: J Neuroinflammation Date: 2021-01-30 Impact factor: 8.322
Authors: Diana Ferraro; Sara De Biasi; Anna Maria Simone; Riccardo Orlandi; Milena Nasi; Francesca Vitetta; Marcello Pinti; Marco Fogliani; Stefano Meletti; Andrea Cossarizza; Patrizia Sola Journal: Cells Date: 2021-11-26 Impact factor: 6.600